Knome

Knome was co-founded in 2007 by Harvard genomics ace George Church.

Knome made headlines in its early days when it said it sequenced and analyzed the genomes of three wealthy people for the cool sum of $350,000 each.

A year later, the price dropped to $100,000, which meant that a few more folks with genetic diseases in their families were able to afford what it took to scrutinize their genomes.

But only now that commercially available sequencers can blaze through an entire 6-billion letter human genome for less than $5,000, Knome has been able to branch out its business to appeal to a whole lot more people.

Molecular biologists and biochemists, for starters, are increasingly becoming curious about using the new tools of genomics for their experiments. But they typically don’t have the math and statistics background to make much sense of the data.

People who are trained in bioinformatics who can help analyze and visualize these massive piles of raw data, as you might imagine, are in short supply and high demand these days.

As academics start dreaming up all kinds of questions they can realistically ask through sequencing genomes for $5,000 a person, and Big Pharma companies even start to mull whether to sequence patients in their clinical drug trials, it’s created a broader base of interest in the kind of more automated genomic analysis and interpretation that Knome was built to provide.

Knome is a private company, and doesn’t say much about its finances, but it is showing signs of gaining traction in its fourth year of operations. The company has built up a team of 30 employees in Cambridge, plus another 10 in India.

Knome has recently come out with a version 2.0 of its software. Researchers from Harvard Medical School, the Mayo Clinic, the University of British Columbia, the University of Seoul, have started using the service, among others, Conde says.

Knome, financed by the founders in the beginning, has now pulled in a total of $12 million in investment capital from the founders, angels, France-based bioMerieux, and one more unnamed strategic investor.

The latest strategic investment, worth $5 million, arrived in July 2011, according to a regulatory filing. Knome now plans to “hire aggressively,” and currently lists seven openings on its company site.

Conde wouldn’t disclose actual revenues, or Knome’s growth projections, but he did say in the first quarter of 2011, the company generated more revenue than it had in its cumulative history to that point.

The founding idea in 2007, “was to make genomics accessible to the public.” But the cost of the sequencing in the first three years was still so high, there was no way it could be truly accessible, and only a select few genomics experts and bioinformaticians were able to use the Knome service.

But now that Illumina, Life Technologies and Complete Genomics have all developed commercial sequencing technologies that can go for less than $5,000 a genome, Knome has found more interest in its software (called kGAP 2.0) that can compare new genomes sequenced on the various instruments vs. what is known in the scientific literature about relationships between DNA and disease.